Diabetic Foot Ulcer Treatment Market Report 2026

The diabetic foot ulcer treatment market size has grown strongly in recent years. It will grow from $7.94 billion in 2025 to $8.61 billion in 2026 at a compound annual growth rate (CAGR) of 8.4%. The growth in the historic period can be attributed to high diabetic ulcer recurrence rates, limited effectiveness of traditional treatments, rising hospitalization rates, increasing amputation risk, dependence on clinical wound care.

The diabetic foot ulcer treatment market size is expected to see strong growth in the next few years. It will grow to $11.96 billion in 2030 at a compound annual growth rate (CAGR) of 8.6%. The growth in the forecast period can be attributed to advancements in biologic therapies, increased use of npwt devices, expansion of multidisciplinary care models, growing focus on early intervention, rising investment in wound care innovation. Major trends in the forecast period include rising adoption of advanced wound care dressings, increased use of biologic therapies, growing demand for combination treatment approaches, expansion of therapy device-based treatments, increasing focus on limb salvage strategies.

The rising number of people living with diabetes is expected to drive the growth of the diabetic foot ulcer treatment market in the coming years. Diabetes is a long-term metabolic disorder characterized by elevated blood glucose levels that, over time, can cause serious damage to the heart, blood vessels, eyes, kidneys, and nerves. Diabetes is a primary cause of foot ulcers, which increases the demand for effective diabetic foot ulcer treatments. For instance, in April 2025, according to the International Diabetes Federation, a Belgium-based international non-profit organization representing national diabetes associations, around 589 million adults aged 20-79 were living with diabetes globally, a figure projected to reach 853 million by 2050. Therefore, the growing diabetic population is driving the expansion of the diabetic foot ulcer treatment market.

Major companies operating in the diabetic foot ulcer treatment market are focusing on launching innovative solutions, such as ON101, to strengthen their competitive position. Innovative treatments for diabetic foot ulcers involve advanced approaches aimed at improving wound healing and patient outcomes. For instance, in October 2023, Oneness Biotech Co., a Taiwan-based pharmaceutical company, introduced ON101, a novel topical cream marketed under the brand name Fespixon, for the treatment of diabetic foot ulcers. ON101 is designed for chronic, non-healing DFUs that have not responded to conventional therapies. Clinical trial results showed that the wound-healing cream achieved a 60% complete healing rate within 16 weeks, compared to a 35% healing rate observed with absorbent wound dressings, demonstrating its superior effectiveness.

In August 2023, Coloplast, a Denmark-based company that develops healthcare products and services, acquired Kerecis for an undisclosed amount. Through this acquisition, the companies aim to advance and expand access to innovative diabetic foot ulcer treatments by leveraging Kerecis’ fish skin-based wound care technology. The combined product portfolios offer a wider range of wound care solutions, enabling healthcare professionals to better address the specific needs of patients with diabetic foot ulcers. Kerecis is an Iceland-based company specializing in fish skin grafts for the treatment of diabetic foot ulcers.

Major companies operating in the diabetic foot ulcer treatment market are Coloplast A/S, Medtronic PLC, Molnlycke Health Care AB, B. Braun Melsungen AG, Medline Industries Inc., ConvaTec Inc., Acelity L.P. Inc., 3M Healthcare, Smith & Nephew PLC, Organogenesis Inc., BSN Medical GMBH, Integra LifeSciences Corporation, Derma Sciences Inc., Advancis Medical, Tissue Regenix Group PLC, MiMedx Group Inc., Kerecis, Human Regenerative Technologies LLC, AOTI Inc., Lohmann & Rauscher International GmbH & Co. KG, Urgo Medical, L&R USA Inc., Misonix Inc., Bioventus, Cellumed Co. Ltd.

North America was the largest region in the diabetic foot ulcer treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the diabetic foot ulcer treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the diabetic foot ulcer treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the diabetic foot ulcer treatment market by increasing costs of imported biologics, therapy devices, antibiotics, and wound care consumables. North America and Europe are most affected due to dependence on advanced imported treatment products, while Asia-Pacific faces rising device costs. These tariffs elevate treatment expenses. However, they are also driving domestic manufacturing of wound care products and improving regional treatment accessibility.

The diabetic foot ulcer treatment market research report is one of a series of new reports that provides diabetic foot ulcer treatment market statistics, including diabetic foot ulcer treatment industry global market size, regional shares, competitors with a diabetic foot ulcer treatment market share, detailed diabetic foot ulcer treatment market segments, market trends and opportunities, and any further data you may need to thrive in the diabetic foot ulcer treatment industry. This diabetic foot ulcer treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

A diabetic foot ulcer refers to a skin lesion involving full-thickness skin loss on the foot, caused by neuropathic and vascular complications in patients with diabetes mellitus. These complications slow the healing of wounds and increase the risk of infection. Diabetic foot ulcer treatment focuses on preventing, managing, and treating foot ulcers in diabetic patients to reduce the risk of severe complications such as amputation if left untreated.

The main types of diabetic foot ulcer treatments include wound care dressings, biologics, therapy devices, antibiotic medications, and other treatments. Wound care dressings are sterile coverings applied to wounds to protect them from further injury and support the healing process. These dressings help promote faster wound recovery. The primary ulcer types include neuropathic ulcers, ischemic ulcers, and neuro-ischemic ulcers, which are classified into grade 1, grade 2, grade 3, grade 4, and grade 5. Diabetic foot ulcer treatments are utilized by hospitals, ambulatory surgery centers, and other end users.

The diabetic foot ulcer treatment market includes revenues earned by entities by ultrasound therapy, negative pressure wound therapy, and active therapies. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.